The European Commission has approved Biomarin Pharmaceuticals’ Voxzogos (vosoritide) for treating achondroplasia, a common form of dwarfism, in children.

Participants in mid- and late-stage clinical trials who received the treatment were shown to achieve height gain, the San Rafael, Calif., drugmaker said.  The marketing authorization marks the first European approval for treating children with achondroplasia.

Voxzogos is also under review by the FDA for the indication and the agency is expected to reach a decision by Nov. 20.